Initial Series A raise of $350 million funding Areteia Phase III development program of dexpramipexole in eosinophilic asthma, including three ongoing Phase III clinical trials Additional funding ...

Areteia Therapeutic’s CEO, Jorge Bartolome, shared his company’s novel and first oral drug development to treat eosinophilic asthma. During the J.P. Morgan 43rd Annual Healthcare Conference in ...

Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Elyse Stock, M.D. to the Areteia Board of Directors, effective April 17, 202 To Board of Directors April 20, 2023 07: ...

CHAPEL HILL, N.C., January 09, 2025--Areteia Therapeutics, Inc. ("Areteia"), a clinical-stage biotechnology company developing novel inflammation and immunology therapies, with an initial focus on ...

CHAPEL HILL, N.C., March 26, 2025--Areteia Therapeutics, Inc. ("Areteia") today announced that effective immediately its Board of Directors has appointed Donald J. Hayden, Jr. as Chair of the ...

Areteia Therapeutics Inc. has launched to put its lead candidate, dexpramipexole, an oral treatment for eosinophilic asthma, through a phase III trial. Areteia was created by Knopp Biosciences LLC, ...

Areteia Therapeutics announced today that the first patients have been dosed in both the EXHALE-2 and EXHALE-4 trials as part of its overall Phase III clinical program investigating the efficacy and ...

Areteia Therapeutics, Inc. (“Areteia”) today announced that effective immediately its Board of Directors has appointed Donald J. Hayden, Jr. as Chair of the Board and Ian F. Smith as Chair of ...

Areteia Therapeutics Inc. has launched to put its lead candidate, dexpramipexole, an oral treatment for eosinophilic asthma, through a phase III trial. Areteia was created by Knopp Biosciences LLC, ...

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Elyse Stock, M.D. to the Areteia Board of Directors, effective April 17, 2023. Dr. Stock ...

CHAPEL HILL, N.C., March 26, 2025--Areteia Therapeutics, Inc. ("Areteia") today announced that effective immediately its Board of Directors has appointed Donald J. Hayden, Jr. as Chair of the Board ...